Yuanbin Chen is an Oncology physician affiliated with Cancer Treatment Centers of America. OpenAlex indexes 139 publications with 669 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1400 S Orange Ave
Orlando, FL 328062134
Telephone
877-876-3627Provider last certified this registry record 8 Aug 2025.
Industry payments
63 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202537 payments$46,672openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year202520 payments$21,201openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year202513 payments$17,572openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
87.7%PD-1 inhibitor61.1%Nivolumab91%Pembrolizumab9%Part B, office-administered≥24 patientsMicrotubule Inhibitor8.1%Paclitaxel100%Part B, office-administered≥17 patients+ 9 more classes in this area
Metabolism & gastrointestinal
5.8%Other antiemetics4%Fosaprepitant100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist1.5%Palonosetron hcl97%Ondansetron Odt3%Part D + Part B≥38 patients+ 6 more classes in this area
Hormonal (systemic)
2.9%Somatostatin Analog2.8%Lanreotide100%Part B, office-administered≥12 patientsl-Thyroxine0.1%Levothyroxine Sodium100%Part D≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”